<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00961350</url>
  </required_header>
  <id_info>
    <org_study_id>PA32540-301</org_study_id>
    <nct_id>NCT00961350</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers</brief_title>
  <official_title>A 6-Month, Phase 3, Randomized, Double-Blind, Parallel-Group, Controlled, Multi-Center Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>POZEN</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>POZEN</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary: To demonstrate that PA32540 causes fewer gastric ulcers in subjects at risk for
      developing aspirin-associated gastric ulcers compared to enteric coated (EC) aspirin 325 mg.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Gastric Ulcer Confirmed by Endoscopy(EC) Aspirin 325 mg</measure>
    <time_frame>6 months</time_frame>
    <description>The primary efficacy endpoint was the number of subjects with gastric ulcers at any time throughout 6 months of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter (measured by close application of open endoscopic biopsy forceps) with unequivocal crater depth. A subject is considered to have completed the study if all scheduled assessments up through the 6 month visit have been performed or if the endpoint of gastric ulcer confirmed by endoscopy has been reached.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Number of Participants With Gastric and/or Duodenal Ulcers</measure>
    <time_frame>6 Months</time_frame>
    <description>The Number of Participants with Gastric and/or Duodenal Ulcers throughout 6 months of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Subjects With &quot;Treatment Success&quot;</measure>
    <time_frame>6 Months</time_frame>
    <description>Those Subjects Without Gastric Ulcers and Without Upper Gastrointestinal (UGI) Adverse Events leading to discontinuation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Participants Discontinuing From the Study Due to NSAID-Associated Upper GI Adverse Events</measure>
    <time_frame>6 months</time_frame>
    <description>The Number of Participants Discontinuing from the Study Due to non-steroidal anti-inflammatory drug (NSAID)-Associated Upper GI Adverse Events during the treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Participants With Heartburn Resolution at 6 Months, ie no Heartburn Symptoms During the Last 7 Days Prior to the Visit</measure>
    <time_frame>6 Months</time_frame>
    <description>Subjects were asked whether heartburn symptoms within the 7 days prior to the visit were:
none: no symptoms
mild: awareness of symptom, but easily tolerated
moderate: discomforting symptom sufficient to cause interference with normal activities (including sleep)
severe: incapacitating symptom, with inability to perform normal activities (including sleep) Heartburn was defined as a burning feeling rising from the stomach or lower part of the chest towards the neck.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">530</enrollment>
  <condition>Gastric Ulcer</condition>
  <arm_group>
    <arm_group_label>PA32540</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EC Aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The comparator aspirin 325 mg enteric coated tablet (PA32540 minus omeprazole)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PA32540</intervention_name>
    <description>PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole</description>
    <arm_group_label>PA32540</arm_group_label>
    <other_name>YOSPRALA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EC Aspirin 325</intervention_name>
    <description>The comparator aspirin 325 mg enteric coated tablet (PA32540 minus omeprazole)</description>
    <arm_group_label>EC Aspirin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. A. Male or non-pregnant, non-breastfeeding females who have been on daily aspirin 325
             mg for at least three months and who are expected to use daily aspirin 325 mg for at
             least six months (Daily is defined as &quot;at least 5 days per week&quot;):

             AND, who are

               -  55 years of age and older; or

               -  18 - 54 years of age and have a history of a documented gastric or duodenal ulcer
                  within the past five years.

          2. A. Aspirin use should be for the secondary prevention of cardiovascular or
             cerebrovascular events as defined as follows:

             Have been diagnosed with or have had a history of

               -  MI (myocardial infarction that has been confirmed or suspected)

               -  Ischemic stroke

               -  TIA (transient ischemic attack)

             Or have established, clinically significant coronary and other atherosclerotic
             vascular disease (meaning at high risk for surgical intervention or for MI, TIA,
             stroke, if left untreated), including:

               -  Angina (stable or unstable)

               -  Peripheral arterial disease

               -  Atherosclerotic aortic disease

               -  Carotid artery disease Or have had

               -  CABG (coronary artery bypass graft)

               -  PCI (percutaneous coronary intervention with or without stent)

               -  Carotid endarterectomy

          3. A. If female, subjects are eligible if they are of

               1. non-childbearing potential (i.e., physiologically incapable of becoming
                  pregnant); or,

               2. childbearing potential, have a negative pregnancy test at screening, and at least
                  one of the following applies or is agreed to by the subject:

                    -  Female sterilization or sterilization of male partner

                    -  Hormonal contraception by oral route, implant, injectable, vaginal ring

                    -  Any intrauterine device (IUD) with published data showing that the lowest
                       expected failure rate is less than 1% per year

                    -  Double barrier method (2 physical barriers or 1 physical barrier plus
                       spermicide)

                    -  Any other method with published data showing that the lowest expected
                       failure rate is less than 1% per year 4. Able to understand and comply with
                       study procedures required and able and willing to provide written informed
                       consent prior to any study procedures being performed

        Exclusion criteria:

          1. Baseline endoscopy showing any gastric, esophageal or duodenal ulcer at least 3 mm in
             diameter with depth

          2. Positive test result for H. pylori at screening 3A. Have had a revascularization
             procedure (i.e., Coronary Artery Bypass Graft, Percutaneous Transluminal Coronary
             Angioplasty, or carotid endarterectomy) less than six months prior to screening

        4. Unstable hypertension as judged by the Investigator 5. Uncontrolled diabetes mellitus as
        judged by the Investigator 6. Unstable cardio- or cerebrovascular disease such that it
        would endanger the subject if they participated in the trial 7. Clinically significant
        valvular disease 8. Congestive heart failure or other cardiovascular symptoms according to
        New York Heart Association (NYHA) Functional Classification III or IV (Appendix 3) 9.
        History of hypersensitivity to omeprazole or to another proton pump inhibitor 10. History
        of allergic reaction or intolerance to aspirin and/or a history of aspirin-induced symptoms
        of asthma, rhinitis, and/or nasal polyps 11. History of serious UGI event, such as
        bleeding, perforation, or obstruction 12. Gastrointestinal disorder or surgery leading to
        impaired drug absorption 13. Presence of chronic or uncontrolled acute medical illness,
        e.g. gastrointestinal disorder (esophageal stricture, severe esophagitis, long-segment
        Barrett's esophagus, signs and symptoms of gastric outlet obstruction), thyroid disorder
        and/or infection that would endanger a subject if they were to participate in the study 14.
        Schizophrenia, uncontrolled bipolar disorder, or severe depression 15. History of
        alcoholism or drug addiction within a year prior to enrollment in the study 16. Severe
        hepatic dysfunction (i.e. cirrhosis or portal hypertension) 17. Blood coagulation disorder,
        including use of systemic anticoagulants such as warfarin or other vitamin K antagonists
        18. Any condition that, in the opinion of the Investigator, may either put the subject at
        risk or influence the results of the study 19. Use of any excluded concomitant medication
        (see Section 9.2) 20. Screening laboratory ALT or AST value &gt; two times the upper limit of
        normal 21A. History of renal insufficiency 22. Other than noted specifically, any screening
        laboratory value that is clinically significant in the Investigator's opinion and would
        endanger a subject if the subject was to participate in the study 23. Use of an
        investigational treatment in the 4 weeks before screening 24. History of malignancy,
        treated or untreated, within the past five years, with the exception of successfully
        treated basal cell or squamous cell carcinoma of the skin 25. Previous participation in
        another PA32540 clinical research study 26. Subjects, who are employees of the research
        facility, immediately related to the Principal Investigator, or are in some way under the
        supervision of the Principal Investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Pozen</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2009</study_first_submitted>
  <study_first_submitted_qc>August 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2009</study_first_posted>
  <results_first_submitted>October 22, 2015</results_first_submitted>
  <results_first_submitted_qc>December 15, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 21, 2016</results_first_posted>
  <disposition_first_submitted>October 31, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>October 31, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 2, 2012</disposition_first_posted>
  <last_update_submitted>January 20, 2016</last_update_submitted>
  <last_update_submitted_qc>January 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PA32540 is proposed for the secondary prevention of cardio- and cerebrovascular events in patients at risk for developing aspirin-associated gastric ulcers.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Stomach Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Omeprazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PA32540</title>
          <description>PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole dosed once daily (QD)</description>
        </group>
        <group group_id="P2">
          <title>EC Aspirin</title>
          <description>EC Aspirin 325 mg enteric coated tablet (PA32540 minus omeprazole) dosed once daily (QD)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="265"/>
                <participants group_id="P2" count="265"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Intent-to-Treat Population (ITT)</title>
              <participants_list>
                <participants group_id="P1" count="265"/>
                <participants group_id="P2" count="265"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="264">1. One sub rand to PA32540 took EC-Aspirin</participants>
                <participants group_id="P2" count="265"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="218"/>
                <participants group_id="P2" count="198"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="67"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Misc</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PA32540</title>
          <description>PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole dosed once daily (QD)</description>
        </group>
        <group group_id="B2">
          <title>EC Aspirin</title>
          <description>EC Aspirin 325 mg enteric coated tablet (PA32540 minus omeprazole) dosed once daily (QD)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="265"/>
            <count group_id="B2" value="265"/>
            <count group_id="B3" value="530"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.3" spread="7.2"/>
                    <measurement group_id="B2" value="65.8" spread="6.7"/>
                    <measurement group_id="B3" value="66.1" spread="6.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="188"/>
                    <measurement group_id="B2" value="190"/>
                    <measurement group_id="B3" value="378"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Gastric Ulcer Confirmed by Endoscopy(EC) Aspirin 325 mg</title>
        <description>The primary efficacy endpoint was the number of subjects with gastric ulcers at any time throughout 6 months of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter (measured by close application of open endoscopic biopsy forceps) with unequivocal crater depth. A subject is considered to have completed the study if all scheduled assessments up through the 6 month visit have been performed or if the endpoint of gastric ulcer confirmed by endoscopy has been reached.</description>
        <time_frame>6 months</time_frame>
        <population>Intent to Treat (ITT) Population</population>
        <group_list>
          <group group_id="O1">
            <title>PA32540</title>
            <description>PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole dosed once daily (QD)</description>
          </group>
          <group group_id="O2">
            <title>EC Aspirin</title>
            <description>EC Aspirin 325 mg enteric coated tablet (PA32540 minus omeprazole) dosed once daily (QD)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Gastric Ulcer Confirmed by Endoscopy(EC) Aspirin 325 mg</title>
          <description>The primary efficacy endpoint was the number of subjects with gastric ulcers at any time throughout 6 months of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter (measured by close application of open endoscopic biopsy forceps) with unequivocal crater depth. A subject is considered to have completed the study if all scheduled assessments up through the 6 month visit have been performed or if the endpoint of gastric ulcer confirmed by endoscopy has been reached.</description>
          <population>Intent to Treat (ITT) Population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="265"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="1.8" upper_limit="6.8"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary efficacy endpoint was the proportion of subjects with gastric ulcers throughout 6 months of treatment. The primary endpoint was analyzed with the CMH test stratified by NSAID use (COX-2/Other NSAID/No) at randomization. A sample size of 250 subjects/treatment would provide 86% power to detect the difference of 8% between EC aspirin 325 mg (13%) and PA32540 (5%) with a 2-sided significance of 5%; and, provides adequate power to test the key secondary endpoints in sequential order.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.020</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test stratified by NSAID use=COX-2, other NSAID, or NSAID use=NO at randomization.</method_desc>
            <param_type>Proportions</param_type>
            <param_value>3.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.8</ci_lower_limit>
            <ci_upper_limit>6.8</ci_upper_limit>
            <estimate_desc>The proportion is from the PA32540 treatment group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Participants With Gastric and/or Duodenal Ulcers</title>
        <description>The Number of Participants with Gastric and/or Duodenal Ulcers throughout 6 months of treatment.</description>
        <time_frame>6 Months</time_frame>
        <population>Intent to Treat (ITT) Population</population>
        <group_list>
          <group group_id="O1">
            <title>PA32540</title>
            <description>PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole dosed once daily (QD)</description>
          </group>
          <group group_id="O2">
            <title>EC Aspirin</title>
            <description>EC Aspirin 325 mg enteric coated tablet (PA32540 minus omeprazole) dosed once daily (QD)</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants With Gastric and/or Duodenal Ulcers</title>
          <description>The Number of Participants with Gastric and/or Duodenal Ulcers throughout 6 months of treatment.</description>
          <population>Intent to Treat (ITT) Population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="265"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The cumulative proportion of subjects developing gastric ulcers and/or duodenal ulcers at 6 months was analyzed using the CMH test stratified by NSAID use=COX-2, other NSAID, or NSAID use=NO at randomization.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test stratified by NSAID use=COX-2, other NSAID, or NSAID use=NO at randomization.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Subjects With “Treatment Success”</title>
        <description>Those Subjects Without Gastric Ulcers and Without Upper Gastrointestinal (UGI) Adverse Events leading to discontinuation.</description>
        <time_frame>6 Months</time_frame>
        <population>Intent to Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>PA32540</title>
            <description>PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole dosed once daily (QD)</description>
          </group>
          <group group_id="O2">
            <title>EC Aspirin</title>
            <description>EC Aspirin 325 mg enteric coated tablet (PA32540 minus omeprazole) dosed once daily (QD)</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects With “Treatment Success”</title>
          <description>Those Subjects Without Gastric Ulcers and Without Upper Gastrointestinal (UGI) Adverse Events leading to discontinuation.</description>
          <population>Intent to Treat Population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="265"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="249"/>
                    <measurement group_id="O2" value="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The cumulative proportion of subjects with Treatment Success was analyzed using the CMH test stratified by NSAID use=COX-2, other NSAID, or NSAID use=NO at randomization.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test stratified by NSAID use=COX-2, other NSAID, or NSAID use=NO at randomization.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Participants Discontinuing From the Study Due to NSAID-Associated Upper GI Adverse Events</title>
        <description>The Number of Participants Discontinuing from the Study Due to non-steroidal anti-inflammatory drug (NSAID)-Associated Upper GI Adverse Events during the treatment period</description>
        <time_frame>6 months</time_frame>
        <population>Intent to Treat (ITT) Population</population>
        <group_list>
          <group group_id="O1">
            <title>PA32540</title>
            <description>PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole dosed once daily (QD)</description>
          </group>
          <group group_id="O2">
            <title>EC Aspirin</title>
            <description>EC Aspirin 325 mg enteric coated tablet (PA32540 minus omeprazole) dosed once daily (QD)</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants Discontinuing From the Study Due to NSAID-Associated Upper GI Adverse Events</title>
          <description>The Number of Participants Discontinuing from the Study Due to non-steroidal anti-inflammatory drug (NSAID)-Associated Upper GI Adverse Events during the treatment period</description>
          <population>Intent to Treat (ITT) Population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="265"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The cumulative proportion of subjects discontinuing from the study due to NSAID-associated upper GI adverse events was analyzed using the CMH test stratified by NSAID use=COX-2, other NSAID, or NSAID use=NO at randomization.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test stratified by NSAID use=COX-2, other NSAID, or NSAID use=NO at randomization.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Participants With Heartburn Resolution at 6 Months, ie no Heartburn Symptoms During the Last 7 Days Prior to the Visit</title>
        <description>Subjects were asked whether heartburn symptoms within the 7 days prior to the visit were:
none: no symptoms
mild: awareness of symptom, but easily tolerated
moderate: discomforting symptom sufficient to cause interference with normal activities (including sleep)
severe: incapacitating symptom, with inability to perform normal activities (including sleep) Heartburn was defined as a burning feeling rising from the stomach or lower part of the chest towards the neck.</description>
        <time_frame>6 Months</time_frame>
        <population>Intent to Treat (ITT) Population</population>
        <group_list>
          <group group_id="O1">
            <title>PA32540</title>
            <description>PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole dosed once daily (QD)</description>
          </group>
          <group group_id="O2">
            <title>EC Aspirin</title>
            <description>EC Aspirin 325 mg enteric coated tablet (PA32540 minus omeprazole) dosed once daily (QD)</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants With Heartburn Resolution at 6 Months, ie no Heartburn Symptoms During the Last 7 Days Prior to the Visit</title>
          <description>Subjects were asked whether heartburn symptoms within the 7 days prior to the visit were:
none: no symptoms
mild: awareness of symptom, but easily tolerated
moderate: discomforting symptom sufficient to cause interference with normal activities (including sleep)
severe: incapacitating symptom, with inability to perform normal activities (including sleep) Heartburn was defined as a burning feeling rising from the stomach or lower part of the chest towards the neck.</description>
          <population>Intent to Treat (ITT) Population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="265"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="198"/>
                    <measurement group_id="O2" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The proportion of subjects who had no heartburn at 6 months (regardless of the presence or absence of heartburn at baseline) was analyzed using the CMH test stratified by NSAID use=COX-2, other NSAID, or NSAID use=NO at randomization.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test stratified by NSAID use=COX-2, other NSAID, or NSAID use=NO and by baseline heartburn severity at randomization.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Informed consent through 6 months plus 28 days for Serious Adverse Events and Randomization through 6 months for all non-serious adverse events.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>PA32540</title>
          <description>PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole dosed once daily (QD)</description>
        </group>
        <group group_id="E2">
          <title>EC Aspirin</title>
          <description>EC Aspirin 325 mg enteric coated tablet (PA32540 minus omeprazole) dosed once daily (QD)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="264"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="264"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="264"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="264"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="264"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="264"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="264"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="264"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="264"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Pancreatic cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="264"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="264"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Intestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="264"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Infusion site extravasation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="264"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="264"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="264"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="264"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Chest wall abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Sepsis syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="264"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myofascial pain syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="264"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="264"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="264"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="264"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="264"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="264"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (12.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="191" subjects_at_risk="264"/>
                <counts group_id="E2" subjects_affected="224" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="51" subjects_affected="46" subjects_at_risk="264"/>
                <counts group_id="E2" events="48" subjects_affected="44" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="40" subjects_affected="35" subjects_at_risk="264"/>
                <counts group_id="E2" events="114" subjects_affected="90" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" events="29" subjects_affected="27" subjects_at_risk="264"/>
                <counts group_id="E2" events="97" subjects_affected="82" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="264"/>
                <counts group_id="E2" events="26" subjects_affected="26" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" events="17" subjects_affected="15" subjects_at_risk="264"/>
                <counts group_id="E2" events="47" subjects_affected="46" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="264"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="264"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="264"/>
                <counts group_id="E2" events="34" subjects_affected="31" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="264"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Oesophageal disorder</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="264"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Reflux oesophagitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="264"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Erosive duodenitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="264"/>
                <counts group_id="E2" events="26" subjects_affected="25" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="264"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Erosive oesophagitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="264"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="264"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="264"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="264"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="264"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="264"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="264"/>
                <counts group_id="E2" events="13" subjects_affected="10" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PI agrees that the first publication will be a multi-center publication of the study results. Following this multi-center publication, PI can publish, present or use any non-confidential study results following Sponsor review and comment.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John Fort, MD / Chief Medical Officer</name_or_title>
      <organization>POZEN</organization>
      <phone>919-913-1030</phone>
      <email>jfort@pozen.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

